Using a novel murine model (MGS1) that recapitulates the human MG TME, researchers demonstrated that treatment with anti-CSF1/CSF1R antibodies reprogrammed the primary immunosuppressive myeloid cells within the TME. This evidence concerns the gene CSF1 and myasthenia gravis.